NCT02287428 2026-03-12
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
Dana-Farber Cancer Institute
Phase 1 Recruiting
Clinical Trials
6 trialsNCT03223103 2025-09-10
Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma
Albert Einstein College of Medicine
Phase 1 Active not recruiting
NCT04201873 2025-08-22
Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma
Jonsson Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT03422094 2021-10-27
Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Washington University School of Medicine
Phase 1 Terminated
NCT02149225 2018-08-07
GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients
Immatics Biotechnologies GmbH
Phase 1 Completed
NCT02510950 2017-11-17
Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma
Washington University School of Medicine
Phase 1 Terminated